Kissei Pharmaceutical revised its consolidated earnings forecasts for the six-month period ending September 2026. While maintaining its upward revision to net sales, the company expects interim net profit to come in ¥2.3 billion below its previous forecast due to the recognition of a special loss related to Tavneos, its vasculitis treatment.
Kissei Pharmaceutical announced and revised its consolidated earnings forecasts for the six-month period ending September 2026. Forecasts for net sales and ordinary profit were revised upward.
Meanwhile, administrative procedures, including the cancellation of the manufacturing and marketing approval for Tavneos, a vasculitis treatment, are under way, and the company expects to record a special loss in connection with them.
Interim net profit was projected at ¥5.1 billion, ¥2.3 billion below the forecast announced in July.